छोड़कर सामग्री पर जाएँ

Aurobindo Pharma arm enters into license agreement with US company; shares fall

Under the terms of the agreement, CuraTeQ has been granted exclusive license rights to commercialise BFI-751 in all major regulated markets, certain semi-regulated, and emerging markets worldwide.

Read More

​ Under the terms of the agreement, CuraTeQ has been granted exclusive license rights to commercialise BFI-751 in all major regulated markets, certain semi-regulated, and emerging markets worldwide. Under the terms of the agreement, CuraTeQ has been granted exclusive license rights to commercialise BFI-751 in all major regulated markets, certain semi-regulated, and emerging markets worldwide.  Moneycontrol Latest News Read More  

प्रातिक्रिया दे

आपका ईमेल पता प्रकाशित नहीं किया जाएगा. आवश्यक फ़ील्ड चिह्नित हैं *

hi_INहिन्दी